Obinutuzumab binds CD20 on B cells; its Fc is glycoengineered to enhance FcγRIIIa engagement, driving ADCC/ADCP by NK cells/macrophages, and type II binding induces direct caspase‑independent apoptosis (with limited CDC), leading to B‑cell killing.